| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 251.8 | 231.4 | 205.0 |
| Other income | -1.2 | 0.8 | 0.4 |
| Total income | 250.6 | 232.2 | 205.4 |
| Profit before exceptional items & tax | 29.0 | 17.7 | 10.5 |
| Profit before tax | 29.0 | 17.7 | 10.5 |
| Net profit | 21.9 | 12.4 | 7.7 |
| Operating margin | 11.6% | 7.6% | 5.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +184.40% |
|---|---|
| Net profit, quarter on quarter | +76.60% |
| Revenue, year on year | +22.80% |
BSE results filing, NSE: GUFICBIO. Figures extracted from the filing.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹423.75
- Market cap
- ₹4,249 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 57.9×Sector 50.4×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Legal & Regulatory
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
- Value
- ₹0.02 Cr
Gufic BioSciences Credit Rating
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
- Value
- ₹516.0 Cr
Gufic BioSciences Annual General Meeting
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic BioSciences Management Change
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic BioSciences Earnings Call Transcript: Key Takeaways
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
- Call
- Guides 15% growth
Gufic BioSciences Investor Presentation: Key Takeaways
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.